Company Overview and News
KUALA LUMPUR (Aug 27): CCM Duopharma Biotech Bhd’s (CCMD) net profit grew 7.1% to RM10.34 million in the second quarter ended June 30, 2018 (2QFY18) from RM9.65 million a year ago, on higher demand from the private and public health sectors.
7148 BSMAF 1818
Policy changes with the change in government have had an impact on businesses and CCM Duopharma Biotech Bhd (CCMD) is no different.
KUALA LUMPUR: CCM Duopharma Biotech Bhd (CCMD) is looking to acquire potential strategic investments, specifically for stem cell technology, of between RM10 million and RM30 million per investment, and expects to make an acquisition within six months.
TWO quarters after its demerger, the debt-reduction drive of Chemical Company of Malaysia Bhd (CCM) is nearly done. Now, the major task for the management is expanding its chemicals business to cultivate better earnings growth.
CCM Duopharma Biotech Bhd (+ve) SHARES in CCM Duopharma Biotech Bhd (fundamental: 1.3/3, valuation: 1.4/3) triggered our proprietary momentum algorithm for the fifth time this year. Currently trading at about 1.89 times its book value, some 1.88 million shares were traded yesterday, exceeding the counter's 200-day average volume of 315,647 shares.
2018-03-18 themalaymailonline - 1
Tan Sri Abdul Wahid Omar said PNB is today Malaysia’s largest fund manager. — Picture by Zuraneeza ZulkifliKUALA LUMPUR, March 18 — Permodalan Nasional Bhd (PNB), established some 40 years ago, is today the country’s largest fund manager, managing funds worth RM279 billion, said its Group Chairman, Tan Sri Abdul Wahid Omar.
MLYBY MLYNF 4197 7148 1155 4588 4863 5347 5258 SMEBF TNABY 6459 6888 AXXTF MYTEF TNABF BSMAF 1818
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...